» Authors » Dennis Sgroi

Dennis Sgroi

Explore the profile of Dennis Sgroi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 4566
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez D, Sgroi D, Krishnamourthy S, Tearney G
Virchows Arch . 2022 Feb; 480(1):211-227. PMID: 35218378
We will briefly review the current paradigm and some recent developments in the area of clinical breast microscopy, highlighting several promising commercially available, and research-based platforms. Confocal microscopy (reflectance, fluorescence,...
2.
Drago J, Formisano L, Juric D, Niemierko A, Servetto A, Wander S, et al.
Clin Cancer Res . 2019 Aug; 25(21):6443-6451. PMID: 31371343
Purpose: While amplification has been described in breast cancer, the optimal treatment approach for -amplified (FGFR1) metastatic breast cancer (MBC) remains undefined. We evaluated clinical response to endocrine and targeted...
3.
Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, et al.
NPJ Breast Cancer . 2019 Mar; 5:10. PMID: 30911675
Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1 cancer cells...
4.
Aceto N, Bardia A, Wittner B, Donaldson M, OKeefe R, Engstrom A, et al.
Mol Cancer Res . 2018 Feb; 16(4):720-727. PMID: 29453314
Molecular drivers underlying bone metastases in human cancer are not well understood, in part due to constraints in bone tissue sampling. Here, RNA sequencing was performed of circulating tumor cells...
5.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al.
JAMA Oncol . 2018 Feb; 4(4):545-553. PMID: 29450494
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. Objective: To conduct a within-patient comparison...
6.
Alves C, Dey-Guha I, Kabraji S, Yeh A, Talele N, Sole X, et al.
Mol Cancer Ther . 2017 Oct; 17(1):254-263. PMID: 29054988
Human tumor growth depends on rapidly dividing cancer cells driving population expansion. Even advanced tumors, however, contain slowly proliferating cancer cells for reasons that remain unclear. Here, we selectively disrupt...
7.
Kabraji S, Sole X, Huang Y, Bango C, Bowden M, Bardia A, et al.
Breast Cancer Res . 2017 Aug; 19(1):88. PMID: 28764807
Background: Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment responses are likely...
8.
Ebrahimi A, Jung M, Dreyfuss J, Pan H, Sgroi D, Bonner-Weir S, et al.
Islets . 2017 Mar; 9(2):19-29. PMID: 28252345
Isolated islets used for transplantation are known to be stressed, which can result from the circumstances of death, in particular brain death, the preservation of the pancreas with its warm...
9.
Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn L, et al.
Proc Natl Acad Sci U S A . 2017 Jan; 114(5):1033-1038. PMID: 28096337
Breast tumors contain tumorigenic cancer cells, termed "tumor-initiating cells" (TICs), which are capable of both replenishing themselves and giving rise to populations of nontumorigenic breast cancer cells (non-TICs). However, the...
10.
Miles W, Lembo A, Volorio A, Brachtel E, Tian B, Sgroi D, et al.
Cancer Res . 2016 Oct; 76(24):7231-7241. PMID: 27758885
Alternative polyadenylation (APA) is a process that changes the posttranscriptional regulation and translation potential of mRNAs via addition or deletion of 3' untranslated region (3' UTR) sequences. To identify posttranscriptional-regulatory...